Sodium in PDB 8rtn: Human Thrombin in Complex with A Trivalent Inhibitor

All present enzymatic activity of Human Thrombin in Complex with A Trivalent Inhibitor:
3.4.21.5;

The structure of Human Thrombin in Complex with A Trivalent Inhibitor, PDB code: 8rtn was solved by J.Ripoll-Rozada, J.Maxwell, R.J.Payne, P.J.B.Pereira, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	68.86 / 2.51
Space group	H 3 2
Cell size a, b, c (Å), α, β, γ (°)	82.188, 82.188, 271.964, 90, 90, 120
R / Rfree (%)	16.8 / 21.4

The binding sites of Sodium atom in the Human Thrombin in Complex with A Trivalent Inhibitor (pdb code 8rtn). This binding sites where shown within 5.0 Angstroms radius around Sodium atom.
In total only one binding site of Sodium was determined in the Human Thrombin in Complex with A Trivalent Inhibitor, PDB code: 8rtn:

Sodium binding site 1 out of 1 in the Human Thrombin in Complex with A Trivalent Inhibitor


Mono view


Stereo pair view

A full contact list of Sodium with other atoms in the Na binding site number 1 of Human Thrombin in Complex with A Trivalent Inhibitor within 5.0Å range: probe atom residue distance (Å) B Occ H:Na602 b:45.1 occ:1.00 O H:ARG553 2.5 43.6 1.0 O H:HOH767 2.5 40.9 1.0 O H:HOH768 2.6 41.9 1.0 O H:HOH734 2.6 40.0 1.0 O H:LYS556 2.6 36.3 1.0 O H:HOH741 3.0 44.2 1.0 C H:ARG553 3.4 40.9 1.0 N H:ARG553 3.6 32.2 1.0 O H:HOH774 3.7 38.4 1.0 C H:LYS556 3.8 38.7 1.0 O H:TYR510 4.0 43.1 1.0 C H:ASP552 4.0 31.6 1.0 CA H:ARG553 4.1 34.9 1.0 O H:HOH719 4.1 33.9 1.0 CA H:ASP552 4.2 33.1 1.0 N H:ASP554 4.3 37.3 1.0 N H:LYS556 4.3 40.5 1.0 CA H:ASP554 4.5 38.0 1.0 N H:GLY555 4.6 39.2 1.0 CA H:LYS556 4.6 42.6 1.0 OD1 H:ASP552 4.6 32.8 1.0 CD1 H:TYR557 4.7 44.1 1.0 O H:HOH783 4.8 40.1 1.0 O H:ASP552 4.8 32.7 1.0 N H:TYR557 4.8 35.3 1.0 C H:ASP554 4.8 39.9 1.0 CE1 H:TYR557 4.8 47.4 1.0 N H:ASP552 4.9 32.6 1.0 CA H:TYR557 4.9 37.3 1.0

J.Ripoll-Rozada, J.Maxwell, R.J.Payne, P.J.B.Pereira. Human Thrombin in Complex with A Trivalent Inhibitor To Be Published.